NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Ko ...

NEW YORK, July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN).Shareholders who purchased shares of BHVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biohaven-ltd-loss-submission-form/?id=158795&from=4 CLASS PERIOD: March 24, 2023 to May 14, 2 ...

https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=158417&wire=4 BHVN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) The company's product candidate, troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this in ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/biohaven-ltd-lawsuit-sub ...

LOS ANGELES, July 28, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) have opportunity to lead the securities fraud class action lawsuit.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BIOHAVEN LTD. (BHVN), CLICK HERE BEFORE SEPTEMBER 12, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. What Is The Lawsuit About? The complaint filed alleges that, between Marc ...

NEW YORK, July 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN).Shareholders who purchased shares of BHVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biohaven-ltd-loss-submission-form/?id=158131&from=4CLASS PERIOD: March 24, 2023 to May 14, 20 ...

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. and certain officers for alleged violations of federal securities laws during the Class Period from March 24, 2023, to May 14, 2025, seeking damages for affected investors [1][6]. Company Overview - Biohaven is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology, with notable product candidates including troriluzole for spinocerebellar ataxia and BHV-7000 for bipolar disorder [3]. Regulatory Developments - In May 2022, a Phase 3 trial for troriluzole failed to meet its primary endpoint, yet the company continued to promote its regulatory prospects based on post-hoc analyses [4]. - Biohaven submitted a New Drug Application (NDA) for troriluzole to the FDA in May 2023, and the European Medicines Agency (EMA) accepted its Marketing Authorization Application (MAA) in October 2023 [5]. Allegations of Misleading Statements - Throughout the Class Period, Biohaven's executives allegedly made materially false and misleading statements regarding the company's business and the regulatory prospects of its products, particularly regarding troriluzole and BHV-7000 [6]. Stock Price Reactions - Following the FDA's rejection of the troriluzole NDA on July 27, 2023, Biohaven's stock price dropped by $5.38, or 22.61%, closing at $18.42 [7]. - On March 3, 2025, after disclosing disappointing data for BHV-7000, the stock fell by $5.12, or 13.77%, to $32.06 [9]. - Reports of the withdrawal of the troriluzole MAA led to a stock price decline of $3.56, or 15.21%, closing at $19.84 on April 25, 2025 [10]. - On May 14, 2025, the announcement of an extended review period for the troriluzole NDA resulted in a further stock price drop of $3.84, or 19.53%, to $15.82 [11].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 12, 2025 deadline [2]. - The lawsuit claims that throughout the class period, Biohaven made false and misleading statements regarding the regulatory prospects of its drug troriluzole and its efficacy for treating bipolar disorder, which negatively impacted the company's business and financial condition [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3].

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/biohaven-ltd-lawsuit-sub ...

BENSALEM, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to howardsmith@howardsmithla ...